新型试剂盒能捕捉早期肺癌“分子信号”

Core Insights - The research team led by Hu Haike at the Hangzhou Institute of Medicine has developed the world's first diagnostic kit for distinguishing between benign and malignant lung nodules, which has received regulatory approval as a Class III medical device in China [1][2] - Lung cancer remains the most prevalent and deadly cancer in China, with approximately 150 million people suffering from lung nodules, of which over 95% are benign [1] Group 1: Product Development - The team has focused on early lung cancer diagnosis since 2016, utilizing tumor-specific antibody detection technology to identify specific biomarkers [2] - They have screened over 400 key proteins related to early lung cancer using high-throughput screening techniques and artificial intelligence, resulting in a combination of 13 optimal diagnostic markers, including 8 novel markers [2] Group 2: Clinical Testing and Performance - The diagnostic kit was tested in multiple hospitals, involving 1,463 patients with lung nodules, of which 794 were lung cancer cases, with early-stage lung cancer samples accounting for 58.19% [2] - The kit demonstrated a sensitivity of over 65% for early lung cancer detection, significantly outperforming traditional tumor markers, and can increase diagnostic accuracy for atypical small nodules to over 85% when used alongside low-dose spiral CT [2] Group 3: Market Potential - The diagnostic kit is expected to be launched in the market after the Spring Festival, providing crucial support for China's "Healthy China 2030" cancer early screening strategy [2]